Skip to main content

Advertisement

Table 1 Patients characteristics

From: FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

Characteristic No. of patients (%)
No. of patients 101   
Sex
 Male 83   (82)
 Female 18   (18)
Age, years
  Median (Range) 65 (32–82)  
Pathology
  Clear cell 86   (85)
  Papillary 6   (6)
  Clear cell/Sarcomatoid 4   (4)
  Sarcomatoid 2   (2)
  Hemodialyssis 2   (2)
  Unclassified 1   (1)
Prior nephrectomy
  Yes 77   (76)
  No 24   (24)
Disease status
  Recurrent 61   (60)
   Metastatic   58 (57)
   Regional   3 (3)
  Stage IV 40   (40)
   Locoregional   4 (4)
   Metastatic   36 (36)
Prior systematic Therapy
  Yes 17   (17)
   IFN-α   9  
   IFN-α/sorafenib   2  
   Sorafenib   2  
   Sunitinib   1  
   S-1   1  
   IFN-α/UFT   1  
   Sorafenib/Temsirolimus   1  
  No 84   83
  1. Abbreviation: IFN-α interferon-α